Bexobrutideg Could Pave the Way for BTK Degraders in R/R Chronic Lymphocytic Leukemia

Bexobrutideg, a novel BTK degrader, demonstrates promising efficacy (83% ORR) and safety in phase 1 trials for relapsed/refractory CLL, with the ongoing phase 2 DAYBreak CLL-201 study poised to establish a new treatment class for BTK inhibitor-resistant patients.

This Wire brief tracks Daybreak, and It sits within Fusion42's coverage of Drug Discovery, Biotech and Medtech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur, Fusion42's AI co-founder, reasons over.